Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

1. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy)

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) Chronic obstructiv Chronic obstructive pulmonary disease: e pulmonary disease: fluticasone furoate, umeclidinium and vilanterol fluticasone furoate, umeclidinium and vilanterol (T (T relegy) relegy) Evidence summary Published: 14 June 2018 nice.org.uk/guidance/es18 pathways K Ke ey points y points The content of this evidence summary was up-to-date in June 2018. See summaries of product (...) characteristics (SPC), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Regulatory status: Regulatory status: Fluticasone furoate/umeclidinium/vilanterol (Trelegy, GlaxoSmithKline UK) received a European marketing authorisation in November 2017. This triple-therapy inhaler contains an inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA). It is licensed for maintenance treatment of adults with moderate- to-severe

2018 National Institute for Health and Clinical Excellence - Advice

2. Fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta) - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta) - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) Published 12 February 2018 Product Update fluticasone furoate, umeclidinium, vilanterol (as trifenatate) 92 micrograms / 55 micrograms / 22 micrograms inhalation powder (Trelegy ® Ellipta ® ) SMC No 1303/18 GlaxoSmithKline UK 12 January 2018 The Scottish Medicines Consortium (SMC) has completed its assessment (...) of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission fluticasone furoate / umeclidinium / vilanterol (as trifenatate) (Trelegy ® Ellipta ® ) is accepted for restricted use within NHS Scotland. Indication under review: maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated

2018 Scottish Medicines Consortium

3. A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - Full Text View - ClinicalTrials.gov Hide glossary (...) Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease

2015 Clinical Trials

4. Vilanterol and fluticasone furoate for asthma. Full Text available with Trip Pro

Vilanterol and fluticasone furoate for asthma. Vilanterol (VI) is a long-acting beta2-agonist (LABA) that binds to the beta2-adrenoceptor on the airway smooth muscle, producing bronchodilation. LABA therapy, which is well established in adults as part of the British Thoracic Society (BTS) Guidelines for the Management of Asthma, leads to improvement in symptoms and lung function and reduction in exacerbations. At present, the commonly used LABAs licensed for use in asthma management (formoterol (...) overall.We included 10 comparisons in this review, seven for which the dose of VI and FF was 100/25 mcg (VI/FF 100/25 mcg vs placebo; VI/FF 100/25 mcg vs same dose of FF; VI/FF 100/25 mcg vs same dose of VI; VI/FF 100/25 mcg vs fluticasone propionate (FP) 500 mcg twice-daily; VI/FF 100/25 mcg vs fluticasone propionate/salmeterol (FP/SAL) 250/50 mcg twice-daily; VI/FF 100/25 mcg vs FP/SAL 250/25 mcg twice-daily; FF/VI 100/25 vs FP/SAL500/50) and three for which the dose of VI and FF was 200/25 mcg (VI/FF

2016 Cochrane Controlled trial quality: predicted high

5. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. Full Text available with Trip Pro

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.We conducted a 52-week, randomized, double-blind, double-dummy, noninferiority (...) trial. Patients who had COPD with a history of at least one exacerbation during the previous year were randomly assigned to receive, by inhalation, either the LABA indacaterol (110 μg) plus the LAMA glycopyrronium (50 μg) once daily or the LABA salmeterol (50 μg) plus the inhaled glucocorticoid fluticasone (500 μg) twice daily. The primary outcome was the annual rate of all COPD exacerbations.A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol

2016 NEJM Controlled trial quality: predicted high

6. Fluticasone/formoterol (Flutiform) - the regular treatment of asthma in children aged 5 to 12 years

Fluticasone/formoterol (Flutiform) - the regular treatment of asthma in children aged 5 to 12 years 1 Published 10 June 2019 1 Product update SMC2178 fluticasone propionate/formoterol fumarate metered dose inhaler 50 microgram/5 microgram (flutiform®) Napp Pharmaceuticals Ltd 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission fluticasone propionate/formoterol fumarate (flutiform®) is accepted for use within NHSScotland. Indication under review: the regular treatment of asthma in children aged 5 to 12 years where the use of a combination product (an inhaled corticosteroid and a long-acting ß 2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting ß 2 agonist. Or • For patients

2019 Scottish Medicines Consortium

7. Oral Low-Dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients with Severe COPD: A Pilot Clinical Trial. (Abstract)

Oral Low-Dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients with Severe COPD: A Pilot Clinical Trial. COPD is characterized by chronic inflammation. In vitro and ex vivo observations suggest that this inflammatory response is partially resistant to the effect of corticosteroids and that low-dose theophylline can restore this response via enhancement of histone deacetylase (HDAC) activity. Whether this occurs in vivo and what its potential

2016 Chest Controlled trial quality: predicted high

8. Azelastine hydrochloride and fluticasone propionate (Dymista nasal spray suspension) - moderate to severe seasonal and perennial allergic rhinitis

Azelastine hydrochloride and fluticasone propionate (Dymista nasal spray suspension) - moderate to severe seasonal and perennial allergic rhinitis HAS - Medical, Economic and Public Health Assessment Division 1/17 Opinion 2 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 5 February 2014 DYMISTA 137 µg/50 µg, nasal spray suspension Bottle with 23 g suspension of 25 ml or around 120 doses (CIP: 34009 275 631 1 9 (...) ) Applicant: MEDA PHARMA INN Azelastine hydrochloride, fluticasone propionate. ATC Code (2013): R01AD58 (nasal corticosteroid, combinations) Reason for the request Inclusion Lists concerned National Health Insurance (French Social Security Code L.162-17) Hospital use (French Public Health Code L.5123-2) Indications concerned "Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient

2014 Haute Autorite de sante

9. [Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children]. Full Text available with Trip Pro

[Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children]. To assess the incremental cost-effectiveness of SFC compared with MON for the control of persistent asthma in children.We conducted an economic evaluation on a 12-week prospective randomized open-label parallel-group comparison of SFC versus MON in children with symptomatic asthma receiving inhaled corticosteroids and short-acting β2-agonists. Asthma-related

2011 Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research Controlled trial quality: uncertain

10. Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2018 Clinical Trials

11. fluticasone furoate/vilanterol (Breo Ellipta )

fluticasone furoate/vilanterol (Breo Ellipta ) fluticasone furoate/vilanterol | CADTH.ca Find the information you need fluticasone furoate/vilanterol fluticasone furoate/vilanterol Last Updated: December 14, 2017 Result type: Reports Project Number: SR0524-000 Product Line: Generic Name: fluticasone furoate/vilanterol Brand Name: Breo Ellipta Manufacturer: GlaxoSmithKline Inc. Indications: COPD Submission Type: Resubmission Project Status: Withdrawn Biosimilar: No Key Milestones 2 Call

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

12. Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma

Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02502734 Recruitment Status : Completed First Posted : July 20, 2015 Results First Posted : July 29, 2016 Last Update Posted

2015 Clinical Trials

13. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study. Full Text available with Trip Pro

Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study. The Asthma Salford Lung Study demonstrated the effectiveness of initiating once-daily fluticasone furoate/vilanterol (FF/VI) versus continuing usual care in asthma patients in UK primary care [ 1 ]. Here, we report a secondary analysis in a subset of patients with fluticasone propionate/salmeterol (FP/Salm) as their baseline intended maintenance therapy

2018 Journal of Asthma Controlled trial quality: predicted high

14. The use of large volume low pressure nasal saline with fluticasone propionate for the treatment of pediatric acute rhinosinusitis. (Abstract)

The use of large volume low pressure nasal saline with fluticasone propionate for the treatment of pediatric acute rhinosinusitis. Fluticasone propionate and nasal saline irrigation have been used in the treatment of sinonasal diseases for a long time. Our study investigates the effect of the combination of large volume low pressure nasal saline irrigation and fluticasone propionate for the treatment of pediatric acute rhinosinusitis.Ninety-one pediatric patients with acute rhinosinusitis were (...) included in our study. The patients were randomized into two groups. The first group (n=45) was treated with standard therapy (antibiotherapy+nasal decongestant) for 2 weeks, the second group was treated with the large volume low pressure nasal saline+fluticasone propionate combination for 3 weeks. The clinical scores, radiologic evaluations (X-ray Waters view), peak nasal inspiratory flow (PNIF) measurements, total symptom scores and hematologic parameters (WBC, CRP, ESR) of the patients were

2014 International journal of pediatric otorhinolaryngology Controlled trial quality: uncertain

15. Fluticasone furoate/vilanterol (as trifenatate) (Relvar Ellipta) - for the regular treatment of asthma

Fluticasone furoate/vilanterol (as trifenatate) (Relvar Ellipta) - for the regular treatment of asthma Final Appraisal Recommendation Advice No: 2014 – July 2014 Fluticasone furoate/vilanterol (as trifenatate) (Relvar ® Ellipta ® ? ) 92/22 micrograms and 184/22 micrograms inhalation powder Submission by GlaxoSmithKline In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1216), which includes the AWMSG (...) of AWMSG Fluticasone furoate/vilanterol (Relvar ® Ellipta ® ? ) is recommended as an option for use within NHS Wales for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: ? patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists. Statement of use: No part of this recommendation may be reproduced

2014 All Wales Medicines Strategy Group

16. A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD) A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD) The safety and scientific validity of this study

2013 Clinical Trials

17. Effects of Tiotropium and Salmeterol/Fluticasone Propionate on Airway Wall Thickness in Chronic Obstructive Pulmonary Disease. Full Text available with Trip Pro

Effects of Tiotropium and Salmeterol/Fluticasone Propionate on Airway Wall Thickness in Chronic Obstructive Pulmonary Disease. Triple inhalation therapy with tiotropium (Tio) and salmeterol/fluticasone propionate combination (SFC) is widely used in the treatment of chronic obstructive pulmonary disease (COPD). However, the effects of triple therapy on airway structural changes remain unknown.The aim of the study was to assess the effects of Tio, salmeterol (SM), SFC and Tio plus SFC on airway

2013 Respiration; international review of thoracic diseases

18. Fluticasone

Fluticasone Top results for fluticasone - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for fluticasone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

19. Aerivio Spiromax (salmeterol xinafoate / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive

Aerivio Spiromax (salmeterol xinafoate / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 23 June 2016 EMA/486136/2016 Committee for Medicinal Products (...) for Human Use (CHMP) Assessment report Aerivio Spiromax International non-proprietary name: salmeterol / fluticasone propionate Procedure No. EMEA/H/C/002752/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/486136/2016 Page 2/50 Table of contents 1. Background information on the procedure 5 1.1. Submission of the dossier 5 1.2. Steps taken for the assessment of the product 7 2. Scientific discussion 8 2.1

2016 European Medicines Agency - EPARs

20. Airexar Spiromax (salmeterol / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive

Airexar Spiromax (salmeterol / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 23 June 2016 EMA/486131/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Airexar Spiromax International non-proprietary name: salmeterol (...) / fluticasone propionate Procedure No. EMEA/H/C/004267/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/486131/2016 Page 2/53 Table of contents 1. Background information on the procedure 6 1.1. Submission of the dossier 6 1.2. Steps taken for the assessment of the product 8 2. Scientific discussion 9 2.1. Introduction 9 2.2. Quality aspects 11 2.2.1. Introduction 11 2.2.2. Active substance 12 Fluticasone propionate

2016 European Medicines Agency - EPARs